Advertisement

Indian Journal of Microbiology

, Volume 52, Issue 3, pp 510–515 | Cite as

Cytomegalovirus Disease in Renal Transplant Recipients: A Single-Center Experience

  • Dharmendra Bhadauria
  • R. K. Sharma
  • A. Kaul
  • Narayan Prasad
  • Amit Gupta
  • Anurag Gupta
  • Aneesh Srivastava
Short Communication

Abstract

Cytomegalovirus (CMV) is the most common viral infection following kidney transplant, has been recognized as a major factor for graft loss and increased incidence of acute rejection. Different studies have reported a variable incidence of CMV disease with the use of Mycophenolate mofetil (MMF). We retrospectively analyzed our renal transplant recipients to review the results of CMV disease and to compare CMV disease in patient on Azathioprine and MMF for this purpose we retrospectively reviewed 521 live related kidney transplant recipients at our institute. 74 (14.2 %) live related allograft recipients developed CMV disease after a median interval of 7.18 ± 4.35 months from transplantation. The mean age was 36.15 ± 10.7 years. 63 of the patients were male. Malaise, fever and diarrhea were among most common symptoms. 20 (27.02 %) of the 74 recipients developed transaminitis, 13 (17.2 %) developed CMV gastritis, 5 (9.13 %) recipients developed pneumonia, and 3 (4.05 %) patient developed colitis. 59 (80 %) patients had leucopenia and 41 (56.5 %) developed thrombocytopenia. Mean serum creatinine level was 1.5 ± 0.4 (0.9–2.4) mg/dl before the disease, 1.9 ± 0.6 (1.3–3.6) mg/dl at the time of the diagnosis, and 1.7 ± 0.06 (0.8–4.2) mg/dl at the end of the treatment. CMV disease developed in 9 (36 %) of recipients who received basiliximab as induction therapy and 13 (30.24 %) of recipients who received ATG (p > 0.05). The incidence of CMV disease was similar in cyclosporine based regimen (13.2 %) and Tacrolimus based regimen 27 (16.16 %) (p = 0.137) and was also similar in Azathioprine 41 (9.5 %) and MMF group 33 (14.3 %) (p = 0.163). There was no significant difference in severity of CMV disease in both groups, except a higher incidence of leucopenia in Azathioprine group (86 vs. 74 %, p < 0.05) as compared to MMF group. 51 (68.91 %) patient developed graft dysfunction during CMV disease. In conclusion we report a low incidence (14.2 %) and milder form of cytomegalovirus disease at our center. Use of universal cytomegalovirus prophylaxis was associated with a low incidence and milder form of the disease. Incidence of CMV disease was similar between Azathioprine and MMF groups.

Keywords

Cytomegalovirus CMV Renal allograft recipient 

References

  1. 1.
    Murray BM, Brentjens J, Amsterdam D, Myers J, Gray V, Pawlowski I, Schewegler K, Singh JP (1997) Monitoring and diagnosis of cytomegalovirus infection in renal transplantation. J Am Soc Nephrol 8(9):1448–1457PubMedGoogle Scholar
  2. 2.
    Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338(24):1741–1751PubMedCrossRefGoogle Scholar
  3. 3.
    Pouteil-Noble C, Ecochard R, Landrivon G, Donia-Maged A, Tardy JC, Bosshard S (1993) Cytomegalovirus infection—an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 55(4):851–857PubMedCrossRefGoogle Scholar
  4. 4.
    Schroeder R et al (2004) Cytomegalovirus disease latent and active infection rates during the first trimester after kidney transplantation. Transplant Proc 36(4):896–898PubMedCrossRefGoogle Scholar
  5. 5.
    Murray BM, Subramaniam S (2004) Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Transpl Infect Dis 6(1):3–9PubMedCrossRefGoogle Scholar
  6. 6.
    Munoz MA, Andres A, Gallego R, Morales E, Morales JM, Aguado JM, Lumbreras C, Torres A, Rodicio JL, Praga M (2002) Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation. Transplant Proc 34:97PubMedCrossRefGoogle Scholar
  7. 7.
    Lebranchu Y, Bridoux F, Büchler M, Meur Y, Etienne I, Toupance O et al (2002) Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Trans 2:48–56CrossRefGoogle Scholar
  8. 8.
    Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D (2004) Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78(4):584–590PubMedCrossRefGoogle Scholar
  9. 9.
    Nemati E, Eizadi M, Moghani Lankarani M, Kardavani B, Khoddami-Vishteh H-R, Kalantar E et al (2007) Cytomegalovirus disease after kidney transplantation: clues to accurate diagnosis. Transplant Proc 39:987–989PubMedCrossRefGoogle Scholar
  10. 10.
    Pour-Reza-Gholi F, Labibi A, Farrokhi F, Nafar M, Firouzan A, Einollahi B (2005) Signs and symptoms of cytomegalovirus disease in kidney transplant recipients. Transplant Proc 37:3056–3058PubMedCrossRefGoogle Scholar
  11. 11.
    Farrugia E, Schwab TR (1992) Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 67:879PubMedGoogle Scholar
  12. 12.
    Abbott KC, Hypolite IO, Viola R, Poropatich RK, Hshieh P, Cruess D et al (2002) Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 6:402–409CrossRefGoogle Scholar
  13. 13.
    Brennan DC (2001) Cytomegalovirus in renal transplantation. J Am Soc Nephrol 12(4):848–855PubMedGoogle Scholar
  14. 14.
    Durlik M, Siennicka J, Litwinska B, Majchrzak J, Trzcinska A, Samsel R et al (2001) Clinical manifestations and diagnosis of cytomegalovirus infection in renal allograft recipients. Transplant Proc 33:651–653PubMedCrossRefGoogle Scholar
  15. 15.
    Basic-Jukic N, Kes P, Bubic-Filipi LJ, Puretic Z, Brunetta B, Pasini J (2005) Does Mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with Azathioprine after cadaveric renal transplantation. Transplant Proc 37:850–851PubMedCrossRefGoogle Scholar
  16. 16.
    Von Muller L et al (2006) Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation. J Med Virol 78(3):394–399CrossRefGoogle Scholar
  17. 17.
    Hagen M, Hjelmesaeth J, Jenssen T, Morkrid L, Hartmann A (2003) A six-year prospective study on new-onset diabetes mellitus, insulin release and insulin sensitivity in renal Transplant recipients. Nephrol Dial Transplant 18:2154–2159PubMedCrossRefGoogle Scholar
  18. 18.
    Toda T, Motoki T, Kurosawa N, Owada E, Achiwa K, Yuhki Y, Tadano K, Takahashi Y, Shimoda N, Shindo J, Harada H, Seki T, Hirano T (2005) Relationship between dose of Mycophenolate mofetil and the occurrence of cytomegalovirus infection and diarrhea in renal transplant recipients. Yakugaku Zasshi 125(2):177–185PubMedCrossRefGoogle Scholar

Copyright information

© Association of Microbiologists of India 2012

Authors and Affiliations

  • Dharmendra Bhadauria
    • 1
  • R. K. Sharma
    • 1
  • A. Kaul
    • 1
  • Narayan Prasad
    • 1
  • Amit Gupta
    • 1
  • Anurag Gupta
    • 1
  • Aneesh Srivastava
    • 2
  1. 1.Department of NephrologySanjay Gandhi Post Graduate Institute of Medical SciencesLucknowIndia
  2. 2.Department of Renal TransplantationSanjay Gandhi Post Graduate Institute of Medical SciencesLucknowIndia

Personalised recommendations